Centessa Pharmaceuticals Future Growth
Future criteria checks 0/6
Centessa Pharmaceuticals is forecast to grow earnings and revenue by 10.2% and 66.2% per annum respectively. EPS is expected to grow by 18.6% per annum. Return on equity is forecast to be -96.7% in 3 years.
Key information
10.2%
Earnings growth rate
18.6%
EPS growth rate
| Biotechs earnings growth | 26.8% |
| Revenue growth rate | 66.2% |
| Future return on equity | -96.7% |
| Analyst coverage | Low |
| Last updated | 14 Aug 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 36 | -198 | -178 | N/A | 4 |
| 12/31/2025 | N/A | -198 | -169 | -176 | 5 |
| 12/31/2024 | N/A | -185 | -165 | -160 | 5 |
| 6/30/2024 | 7 | -157 | -146 | -146 | N/A |
| 3/31/2024 | 7 | -138 | -150 | -150 | N/A |
| 12/31/2023 | 7 | -151 | -161 | -160 | N/A |
| 9/30/2023 | N/A | -157 | -182 | -181 | N/A |
| 6/30/2023 | N/A | -173 | -183 | -183 | N/A |
| 3/31/2023 | N/A | -212 | -199 | -198 | N/A |
| 12/31/2022 | N/A | -216 | -202 | -201 | N/A |
| 9/30/2022 | N/A | -234 | -201 | -205 | N/A |
| 6/30/2022 | N/A | -220 | -195 | -199 | N/A |
| 3/31/2022 | N/A | -197 | -169 | -173 | N/A |
| 12/31/2021 | N/A | -381 | -136 | -136 | N/A |
| 9/30/2021 | N/A | -324 | -88 | -83 | N/A |
| 6/30/2021 | N/A | -286 | -56 | -52 | N/A |
| 3/31/2021 | N/A | -246 | -24 | -20 | N/A |
| 12/31/2020 | N/A | -11 | -11 | -11 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 0ACX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 0ACX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 0ACX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 0ACX is forecast to have no revenue next year.
High Growth Revenue: 0ACX is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 0ACX is forecast to be unprofitable in 3 years.